<DOC>
	<DOCNO>NCT01350999</DOCNO>
	<brief_summary>The purpose study determine safety efficacy TAK-085 , daily ( QD ) twice daily ( BID ) , compare ethyl eicosapentaenoate ( EPA-E ) , three time daily ( TID ) participant hypertriglyceridemia undergoing lifestyle modification .</brief_summary>
	<brief_title>Long-term Efficacy Safety Study TAK-085 Participants With Hypertriglyceridemia</brief_title>
	<detailed_description>TAK-085 oral capsule medicine license Takeda Pharmaceutical Company Ltd. TAK-085 contain omega-3 fatty acid ethyl ( mainly , ethyl eicosapentaenoate ( EPA-E ) ethyl docosahexaenoic acid ( DHA-E ) ) . This phase 3 , open-label , randomize study evaluate efficacy safety TAK-085 . In addition , EPA-E also administer 52 week reference evaluate safety TAK-085 participant hypertriglyceridemia undergo lifestyle modification . The study period total 56 week , comprise 4- week screen period 52 week treatment .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Visit 1 ( Week 4 ) 1 . Undergoing lifestyle modification . 2 . Triglyceride ( TG ) level ( fast state ) 150 mg/dL high less 750 mg/dL Visit 1 ( Week 4 ) . 3 . Both gender , age 20 less 75 year time signing informed consent . 4 . Outpatient . 5 . Capable understand comply protocol requirement . 6 . Signed write , informed consent form prior initiation study procedure . 7 . A female childbearing potential ( premenopausal nonsterilized ) must agree use routinely adequate contraception signing inform consent throughout duration study . Visit 2 ( Week 2 ) 8 . Fasting TG level 150 mg/dL high less 750 mg/dL Visit 2 ( Week 2 ) . 9 . Difference fast low density lipoproteincholesterol ( LDLC ) level Visit 1 ( Week 4 ) Visit 2 ( Week 2 ) within 25 % high value Visit 1 ( Week 4 ) 1 . Any coronary artery disease ( CAD , e.g. , confirm myocardial infarction angina pectoris ) within 6 month prior Visit 1 ( Week 4 ) history revascularization . 2 . Received aortic aneurysmectomy aortic aneurysm within 6 month prior Visit 1 ( Week 4 ) . 3 . History complication clinically significant hemorrhagic disease ( e.g. , hemophilia , capillary fragility illness , digestive tract ulcer , urinary tract haemorrhage , hemoptysis , vitreous haemorrhage ) within 6 month prior Visit 1 ( Week 4 ) . 4 . Diagnosed pancreatitis . 5 . Diagnosed lipoprotein lipase ( LPL ) deficiency , apolipoprotein CII deficiency type III familial hyperlipidemia . 6 . Cushing 's syndrome , uremia , systemic lupus erythematosus ( SLE ) serum dysproteinemia . 7 . Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus define glycosylated hemoglobin ( HbA1C ) level 8.0 % high Visit 1 ( Week 4 ) . 8 . Stage III hypertension define systolic blood pressure 180 mmHg high diastolic blood pressure 110 mmHg high regardless use antihypertensive medication . 9 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level Visit 1 ( Week 4 ) less twice upper limit normal reference range . 10 . If female , pregnant lactating . 11 . Habitual drinking define average daily alcohol intake 100 mL , drug abuse drug dependency , history condition . 12 . Started take antihyperlipidemic drug within 4 week prior Visit 1 ( Week 4 ) . 13 . Received investigational product ( include postmarketing clinical study ) within 12 week prior Visit 1 ( Week 4 ) . 14 . Received TAK085 clinical study . 15 . Judged ineligible study participation investigator subinvestigator reason . Visit 2 ( Week 2 ) 16 . ALT AST level Visit 2 ( Week 2 ) twice upper limit normal reference range high . 17 . Needed change dose antihyperlipidemic drug antidiabetic drug , addition new drug change type drug screen period . 18 . Judged ineligible study participation investigator subinvestigator reason . Visit 3 ( Week 0 ) 19 . Needed change dose antihyperlipidemic drug antidiabetic drug , addition new drug change type drug screen period . 20 . Judged ineligible study participation investigator subinvestigator reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>